Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Edible Drug Delivery Platform Even Faster

December 5, 2019 12:14:02
  • Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause
  • Lexaria’s DehydraTECH platform has generated numerous patents with more pending as a way to provide quick substance delivery to the user’s bloodstream and better access through the blood-brain barrier
  • Lexaria recently announced it had further improved DehydraTECH, as demonstrated in testing that showed early pilot-stage human trial participants began to note edible THC effects in under 10 minutes – more rapidly than the previous DehydraTECH formulation
  • Prior technology testing has focused on animal subjects and non-psychoactive products

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is announcing further advances in its proprietary oral drug delivery platform DehydraTECH™, which is innovating edible consumption of nicotine and cannabis products as a quick-response alternative to inhalation.

Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://cnw.fm/2owxO).

Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.

In June, the company announced that a series of animal studies showed its DehydraTECH solution could improve on cannabidiol (CBD) delivery to the blood system by 811 percent and to brain tissue by 1,937 percent when compared with generic medium-chain triglyceride (MCT) formulations.

The latest announcement marks a new milestone in that the studies involved humans instead of animals and utilized THC instead of CBD, demonstrating further potential applications of DehydraTECH technology.

Speed of onset in the use of various drug products is regarded as a key metric of the products’ potential value, particularly where pain-relief and the relief of other physical torments are concerned. For example, nicotine is recognized as a highly addictive substance that can provoke then alleviate physical withdrawal symptoms or cravings, while certain cannabis extracts have been promoted in recent years as significant remedies for pain and muscle spasms or seizure disorders.

Inhalation has traditionally shown the greatest benefit in terms of rapid-response drug delivery benefits, but Lexaria has been passionate about delivering alternatives because of the harm substance inhalation can do to users’ lungs, as demonstrated by the history of smoking tobacco products and recent concerns about deaths and illnesses linked to vaping cannabis or nicotine products, which in turn have led health insurers to penalize customers who smoke or vape products (http://cnw.fm/7mHhX).

Because of DehydraTECH’s rapid-response capabilities, Lexaria’s technology virtually eliminates a key reason people might risk sustained injury to their lungs in using tobacco and cannabis products. Lexaria’s tech works as a complimentary product with other companies’ research and development on cannabinoids, providing Lexaria a niche as a potential collaborative team member rather than a competitor as other industry developments occur.

Lexaria’s position is further strengthened by its worldwide patents and pending patents for oral or ingestible non-psychoactive cannabinoids – it has been awarded 16 patents in the United States and Australia and is awaiting completion of the process for 60 additional patents in other countries (http://cnw.fm/3uWv8).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.